Recombinant DNA Technology patents are primarily used in the field of Biotechnology for the preparation of Drugs. The total number that is granted by USPTO in this field so far is about 9 Patents.
Some of the interesting technologies patented are listed below. This patent is very important in developing many new Drugs / vaccines which helps the human race to lead their life better. In future this may help in the development of new varied types of drugs.
Patent No: 6,331,609 titled Preparation of human IGF via recombinant DNA technology with the abstract: Human insulin-like growth factor is synthesized in recombinant cell culture by host cells transformed with expression vectors bearing DNA encoding human insulin-like growth factor.
Patent No: 5,958,740 titled, Genetically enhanced cellulase production in Pseudomonas cellulosa using Recombinant DNA Technology with the abstract: An enhanced strain of Pseudomonas celllulosa was obtained by introducing a recombinant genetic construct comprising a heterologous cellulase gene operably connected to a promoter into ATCC 55702, mutagenizing the transformants by treatment with MNNG, and selecting a high cellulase producing transformant. The transformant, designated Pseudomonas cellulosa ATCC XXXX, exhibits enhanced levels of cellulase production relative to the untransformed Pseudomonas cellulosa strain #142 ATCC 55702.
Patent No: 5,928,915 titled, CHO cell sialidase by Recombinant DNA Technology with the abstract : A recombinant cell line has a constitutive sialidase whose functional expression is disrupted, for example by homologous recombination or using antisense RNA. Sialidase is purified from cell culture fluid of Chinese hamster ovary cells. DNA encoding sialidase is obtained using an oligonucleotide probe designed using amino acid sequence data on the sialidase, and the DNA is expressed in host cells transformed with the DNA.
Patent No: 5,770,568 titled, ‘Variants of bovine pancreatic trypsin inhibitor produced by recombinant DNA technology, process expression vector and recombinant host therefor and pharmaceutical use thereof ’ with abstract : Peptides having essentially the sequence of bovine pancreatic trypsin inhibitor (aprotinin) wherein one or more of the amino acids at positions 15, 16, 17, 18, 34, 39 and 52 are replaced by any naturally occurring amino acid produced by recombinant DNA technology, process, expression vector and recominant host therefor and pharmaceutical use thereof. Such peptides being useful as therapeutic agents in diseases connected with the presence of excessive amounts of proteinases.
Patent No: 5,278,285,titled,’ Variant of Kunitz-type inhibitor derived from the .alpha.3-chain of human type VI collagen produced by recombinant DNA technology ’ with abstract : Kunitz-type inhibitor derived from the .alpha.3-chain of human type VI collagen produced by recombinant DNA technology, variants thereof, process, expression vector and recombinant host therefore and pharmaceutical use thereof are disclosed.
Patent No. US 5,015,573 titled DNA vectors and their use in recombinant DNA technology with abstract: A new class of DNA vectors, each comprising two replication systems; a first origin of replication resulting in a low copy number and stable inheritance of the plasmid, and a second, high copy number, origin of replication at which replication is directly controllable such that, when host cells carrying the vector are propagated under a first set of conditions, replication takes mainly from the low copy number origin, and that when said cells are propagated under a second set of conditions, replication takes place also from the high copy number origin to produce a high yield of gene product. The controllable origin of replication may be under the control of a natural promoter of RNA transcription or a substitute promoter such as the PL promoter or lac promoter.
Join Free Patent Lessons Course
